TB-500 dosage reference: typical range 2 – 10 mg, 1–2×/week, cycle 4-week loading + 4–8 week maintenance. Titration chart, reconstitution math and storage.
Naturally occurring peptide involved in cell migration and tissue repair. Promotes flexibility, reduces scar tissue, and supports heart and muscle healing.
Published protocol literature for TB-500 describes a typical range of 2 – 10 mg, dosed 1–2×/week, over a cycle of 4-week loading + 4–8 week maintenance. Reported half-life: several days in circulation (animal models).
| Parameter | Reported value |
|---|---|
| Typical dose range | 2 – 10 mg |
| Frequency | 1–2×/week |
| Cycle length | 4-week loading + 4–8 week maintenance |
| Half-life | Several days in circulation (animal models) |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | BPC-157 (Wolverine Stack), GHK-Cu, IGF-1 LR3 |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how TB-500 dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 2 mg | 1×/week | Loading phase start; basic healing |
| Intermediate | 2.5–5 mg | 2×/week | Enhanced systemic recovery |
| Advanced | 5–10 mg | 2×/week loading, then 2.5mg 1×/week | Intensive repair; 4-week load, then maintain |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 2 mL bacteriostatic water | 2,500 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for TB-500. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for TB-500 generally describes 2 – 10 mg, administered 1–2×/week. Individual protocols vary and should be set by a licensed practitioner.
1–2×/week. Frequency is driven by half-life — TB-500 has a reported half-life of several days in circulation (animal models), so shorter-acting compounds are dosed more often.
Typical cycle length reported is 4-week loading + 4–8 week maintenance. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 2ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
TB-500 is a synthetic fragment of the full TB4 protein. It contains the active region most associated with repair-pathway research.
TB-500 is sold in the U.S. for research, investigational, or licensed professional use only. It is not FDA-approved for human use.